Health
Resilient Pharmaceuticals (formerly Lykos Therapeutics and MAPS PBC), reportedly resubmitted their once-rejected New Drug Application (NDA) for MDMA-assisted therapy for PTSD to the FDA, triggering a fresh review cycle under the agency’s newly finalized psychedelic clinical trial guidance.
The FDA has finalized guidance on clinical investigations into psychedelic-assisted therapies and contract research organization ICON will bring Anthropic’s Claude AI tool into clinical trials involving drug development.
While psychedelics have a history of sparking creativity, the first modern study to investigate the potential of psilocybin to enhance the brain’s ability to unlock creativity and problem solving is underway at the University of Texas, Austin and groups like Center for MINDS is exploring this connection.
Recent research surveying 1,435 microdosers suggests that microdosing’s duration of effect might be more like that of drinking a coffee, with benefits that come and go by day’s end.
A new report from the RAND Corporation shows that nearly one-quarter of U.S. adults now support the legal use of psilocybin with public support driven by approval for therapeutic not personal access or recreational use.
After publishing a new study investigating synthetic analogs for iboga molecules, scientist and co-founder of Gilgamesh Pharmaceuticals, Dalibor Sames, decided to take the compound he has described as an intelligent molecular machine.
The Texas Health and Human Services Commission (HHSC) has announced $50 million in awards to a collective of public universities across the state to establish the Texas Ibogaine Research Consortium.
For millennia, Himalayan tribes have scaled cliffs to obtain psychoactive honey for its medicinal properties. However, in recent years, their sacred gift has been appropriated by thrill-seekers influenced by “podcast bros”, creating health and ecological complications.
New Mexico health officials announced plans to launch the state’s medical psilocybin therapy program by the end of December 2026 – a full year ahead of the legislative deadline.
Supporters of the Freedom To Heal Act met with members of Congress and their staff this week seeking backing for legislation that would allow DEA-regulated medical use of Schedule I substances for patients with life-threatening conditions.
